{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:42:56Z","timestamp":1788385376820,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.nbd.2023.106376","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T02:36:30Z","timestamp":1702348590000},"page":"106376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease"],"prefix":"10.1016","volume":"190","author":[{"given":"Stefan","family":"Bartl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnesh","family":"Kesineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlin","family":"Hencak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa Dal","family":"Cengio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Parth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Salhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Siddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Smrzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Straffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2023.106376_bb0010","series-title":"16th CHDI Meeting 2021, Poster Presentation","article-title":"Modelling the human blood-brain barrier to understand protein spread in Huntington\u2019s disease","author":"Alpaugh","year":"2021"},{"key":"10.1016\/j.nbd.2023.106376_bb0015","first-page":"7120753","article-title":"An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J. Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2023.106376_bb0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.nbd.2023.106376_bb0025","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz","year":"2008","journal-title":"Neurology"},{"issue":"39","key":"10.1016\/j.nbd.2023.106376_bb0030","doi-asserted-by":"crossref","first-page":"E5427","DOI":"10.1073\/pnas.1516217112","article-title":"Transcellular spreading of huntingtin aggregates in the Drosophila brain","volume":"112","author":"Babcock","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.nbd.2023.106376_bb0035","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1468-1331.2008.02173.x","article-title":"Cardiovagal modulation upon postural change is altered in Huntington\u2019s disease","volume":"15","author":"Bar","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"8","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2023.106376_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104943","article-title":"Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: implications for the treatment of Huntington\u2019s disease","volume":"141","author":"Bartl","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106376_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"10.1016\/j.nbd.2023.106376_bb0055","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.nbd.2023.106376_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.nbd.2023.106376_bb0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","article-title":"Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease","volume":"41","author":"Caron","year":"2021","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.nbd.2023.106376_bb0070","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.nbd.2023.106376_bb0075","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington\u2019s disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.03.031","article-title":"Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin","volume":"325","author":"Connolly","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2023.106376_bb0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00225192","article-title":"Somatic expansion of the (CAG)n repead in Huntington disease brains","volume":"95","author":"De Rooij","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.nbd.2023.106376_bb0100","first-page":"41316","article-title":"Impairment of blood-brain barrier is an early event in R6\/2 mouse model of Huntington disease","volume":"7","author":"Di Pardo","year":"2016","journal-title":"Nat. Sci. Rep."},{"key":"10.1016\/j.nbd.2023.106376_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.946822","article-title":"Hunting for the cause: evidence for prion-like mechanism in Huntington\u2019s disease","author":"Donnelly","year":"2022","journal-title":"Front. In Neurosci."},{"key":"10.1016\/j.nbd.2023.106376_bb0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood-brain barrier impairments in Huntington\u2019s disease: potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2023.106376_bib381","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.nbd.2023.106376_bb0115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.09.003","article-title":"Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease","volume":"45","author":"Franciosi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106376_bb0125","doi-asserted-by":"crossref","first-page":"9870","DOI":"10.1038\/s41598-019-46306-5","article-title":"A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer\u2019s disease","volume":"9","author":"Gibbs","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.nbd.2023.106376_bb0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington\u2019s disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.nbd.2023.106376_bb0140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.25862","article-title":"Progressive hepatic mitochondrial dysfunction in premanifest Huntington\u2019s disease","volume":"29","author":"Hoffmann","year":"2014","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.nbd.2023.106376_bb0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12035-014-8932-1","article-title":"Polyglutamine aggregation in Huntington disease: does structure determine toxicity?","volume":"52","author":"Hoffner","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.nbd.2023.106376_bb0155","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbadis.2016.12.015","article-title":"Visualization of prion-like transfer in Huntington\u2019s disease models","volume":"1863","author":"Jansen","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.nbd.2023.106376_bb0160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2023.106376_bb0165","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","article-title":"Dramatic tissue specific mutation lenght increase are an early molecular event in Huntington disease pathogenesis","volume":"12","author":"Kennedy","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.nbd.2023.106376_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5607\/en.2017.26.6.321","article-title":"Cell-to-cell transmission of Polyglutamine aggregates in C. elegans","volume":"26","author":"Kim","year":"2017","journal-title":"Exp. Neurobiol."},{"issue":"2","key":"10.1016\/j.nbd.2023.106376_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2023.106376_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","article-title":"Bone marrow transplantation confers modest benefits in mouse models of Huntington\u2019s disease","volume":"32","author":"Kwan","year":"2012","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.nbd.2023.106376_bb0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archneur.65.4.476","article-title":"Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion","volume":"65","author":"Lali\u0107","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0190","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/ncomms3753","article-title":"Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress","volume":"4","author":"Leitman","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.nbd.2023.106376_bb0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","article-title":"Abnormal in vivo skeletal muscle energy metabolism in Huntington\u2019s disease and dentatorubropallidoluysian atrophy","volume":"48","author":"Lodi","year":"2000","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2023.106376_bb0200","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fnins.2017.00647","article-title":"The evidence for the spread and seeding capacities of the mutant huntingtin protein in in vitro systems and their therapeutic implications","volume":"28","author":"Masnata","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2023.106376_bb0205","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.25354","article-title":"Outcome of cell suspension allografts in a patient with Huntington\u2019s disease","volume":"84","author":"Maxan","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0210","series-title":"EHDN confernce Bologna","article-title":"Update on ongoing clinical trials","author":"McColgan","year":"2022"},{"issue":"43","key":"10.1016\/j.nbd.2023.106376_bb0215","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.1523\/JNEUROSCI.1589-10.2010","article-title":"Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A","volume":"30","author":"Metzler","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2023.106376_bb0220","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant Huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2023.106376_bb0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front. Aging Neurosci."},{"issue":"8","key":"10.1016\/j.nbd.2023.106376_bb0230","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nn.3761","article-title":"Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons","volume":"17","author":"Pecho-Vrieseling","year":"2014","journal-title":"Nat. Neursci."},{"key":"10.1016\/j.nbd.2023.106376_bb0240","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/hmg\/ddaa139","article-title":"Patterns of CAG repeat instability in the central nervous system and periphery in Huntington\u2019s disease and in spinocerebellar ataxia type 1","volume":"29","author":"Pinto","year":"2020","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.nbd.2023.106376_bb0245","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/hmg\/ddq026","article-title":"Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression","volume":"19","author":"Pouladi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2023.106376_bb0250","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington\u2019s disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.nbd.2023.106376_bb0255","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncb1830","article-title":"Cytoplasmic penetzratuion and persistent infection of mammalian cells by polyglutamine aggregates","volume":"11","author":"Ren","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.nbd.2023.106376_bb0260","article-title":"Shedding new light on Huntington\u2019s disease: how blood can both propagate and ameliorate disease pathology","author":"Rieux","year":"2020","journal-title":"Mol. Psychol."},{"key":"10.1016\/j.nbd.2023.106376_bb0265","first-page":"271","article-title":"DNA vaccines","volume":"9","author":"Robinson","year":"1997","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.nbd.2023.106376_bb0270","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mds.20373","article-title":"Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington\u2019s disease","volume":"20","author":"Saft","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2023.106376_bb0275","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","article-title":"Huntington\u2019s disease: the current state of research with peripheral tissues","volume":"219","author":"Sassone","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2023.106376_bb0280","series-title":"16th CHDI meeting","article-title":"Preliminary topline results from GENERATION HD1, a Phase III trial of tominersen in individuals with manifest HD. Clinical session","author":"Schobel","year":"2021"},{"key":"10.1016\/j.nbd.2023.106376_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity a-synuclein antibody, MEDI1341, thaT can entert he brain, sequester extracellular a synuclein and attenuate a synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106376_bb0290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Natur"},{"issue":"13","key":"10.1016\/j.nbd.2023.106376_bb0295","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.nbd.2023.106376_bb0300","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"36","key":"10.1016\/j.nbd.2023.106376_bb0305","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"issue":"43","key":"10.1016\/j.nbd.2023.106376_bb0310","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.nbd.2023.106376_bib385","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A fully humanized transgenic mouse model of Huntington disease","volume":"22","author":"Southwell","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nbd.2023.106376_bb0315","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.nbd.2023.106376_bb0320","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0b013e318282514e","article-title":"Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease","volume":"80","author":"Stuwe","year":"2013","journal-title":"Neurology"},{"issue":"37","key":"10.1016\/j.nbd.2023.106376_bb0330","first-page":"9000","article-title":"Neurobiology of disease mutant huntingtin is secreted via a late endosomal\/lysosomal unconventional secretory pathway","volume":"37","author":"Trajkovic","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.nbd.2023.106376_bb0335","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/hmg\/ddl072","article-title":"Body weight is modulated by levels of full-length Huntingtin","volume":"15","author":"Van Raamsdonk","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.nbd.2023.106376_bb0340","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1083\/jcb.201701047","article-title":"The spread of prion-like proteins by lysosomes and tunneling nanotubes: implications for neurodegenerative diseases","volume":"216","author":"Victoria","year":"2017","journal-title":"J. Cell. Biol."},{"issue":"5","key":"10.1016\/j.nbd.2023.106376_bb0345","first-page":"520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"20","author":"Vidarsson","year":"2014","journal-title":"Front Immuol."},{"issue":"2","key":"10.1016\/j.nbd.2023.106376_bb0350","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/eji.1830180221","article-title":"The half-lives of serum immunoglobulins in adult mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.nbd.2023.106376_bb0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2017.06.006","article-title":"Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies","volume":"449","author":"Vigl","year":"2017","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.nbd.2023.106376_bb0360","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2023.106376_bb0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","article-title":"Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration","volume":"15","author":"Wang","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.nbd.2023.106376_bib382","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ab.2010.11.044","article-title":"Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count","volume":"410","author":"Weiss","year":"2011","journal-title":"Anal Biochem"},{"issue":"5","key":"10.1016\/j.nbd.2023.106376_bb0370","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2023.106376_bb0375","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","article-title":"Huntington disease and the huntingtin protein","volume":"107","author":"Zheng","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.nbd.2023.106376_bb0380","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington\u2019s disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."}],"updated-by":[{"DOI":"10.1016\/j.nbd.2024.106444","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123003923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123003923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:40:42Z","timestamp":1760852442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996123003923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":72,"alternative-id":["S0969996123003923"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106376","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106376"}}